PCN225 TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN COLOMBIA

Autor: van Beurden-Tan, C., Forero, J., Coggia, A., Bustos Márquez, M.C.
Zdroj: In Value in Health November 2019 22 Supplement 3:S480-S480
Databáze: ScienceDirect
Externí odkaz: